Heroes in Drug Discovery.
This award celebrates scientists who have made significant contributions to human healthcare.
The RISE Fellows at Drew University have selected Johnson & Johnson’s drug discovery program of amivantamab as recipients of Drew University’s “Heroes in Drug Discovery” award based on the discovery of the first FDA approved bispecific antibody for the treatment of lung cancer. Lung cancer is one of the most common types of cancer accounting for 25% of all cancer related deaths.
Through the Heroes program, our objective is to celebrate individuals who have made significant contribution to healthcare, as well as connect them to the best and brightest science undergraduates whose passions, interests, and drive position them to be the next leaders in science research.
This event is supported by a grant from Pfizer and administered by the Independent Colleges and Universities of NJ.
Zoom link for the event: https://drew.zoom.us/j/96919256221